U.S.-born Asian Americans no longer the healthiest group among older adults
The report focused on adults aged 50 and older, and used disability prevalence as an indicator for overall health.
The paper shows that while disability rates have decreased among aging adults in every racial group, it's remained unchanged among U.S.-born Asian Americans. The findings suggest that one contributor to the stagnating disability rate is income inequality, which has impacted Asian Americans more than any other group in recent years.
Previous research had shown that both foreign-born and U.S.-born Asian older adults had lower mortality and disability rates than their counterparts in other racial groups. According to the new report, non-Hispanic white Americans have overtaken Asians Americans as the healthiest U.S.-born population, with the lowest disability prevalence.
'This study shows that the 'model minority' stereotype is wrong about the overall experience of U.S.-born older Asians in terms of health,' said lead author Leafia Ye, an assistant sociology professor at the University of Toronto.
The report is the first to focus solely on the health of U.S.-born Asians, a group that experts say has been understudied due to its limited population size. The study drew on data from the American Community Survey, which has a sample size of more than 18 million U.S.-born adults aged 50 and older. The sample size for U.S.-born Asians is roughly 116,000, Ye said.
The study authors defined disability as any chronic physical or mental health condition that limits an older adult's self-care or independent living capacity, which includes carrying out tasks like eating, bathing and grocery-shopping without assistance.
Two decades ago, just 5.5% of U.S.-born Asian elders had trouble living independently — compared with 7% of white and 14% of Black elders.
From 2005 to 2022, the report found, disability rates fell by at least 2% among U.S.-born non-Hispanic white, Black, Hispanic and Indigenous populations, as well as all foreign-born groups. (Black older adults experienced the largest drop from 14% to 10%.) Among native-born older Asian Americans, however, the rate has stayed at 5.5%.
Ye said the trends preceded the Covid-19 pandemic, so it's unlikely that rising anti-Asian racism was a key risk factor.
'What's striking about this study is that U.S.-born Asians are the only group that hasn't experienced improved outcomes,' said Mansha Mirza, principal investigator at the Aging Services Inclusive of Asian American Networks, a national technical assistance and resource development center focused on Asian Americans older adults. Mirza was not involved with the new study.
The trend could be attributed to the fact that U.S.-born Asians 'are more assimilated into the American way of life,' Mirza said, while foreign-born Asians were more likely to 'retain practices from their home countries related to nutrition and diet.'
Disability prevalence varies across the racial group. Cognitive disability is more prevalent in Vietnamese, Filipino and Japanese older adults, according to a 2024 paper in Innovation in Aging. For self-care disability, on the other hand, Vietnamese, Chinese, Filipino and Indian older adults have a higher prevalence.
In the past, older Asian Americans have had better health outcomes than other groups because the large majority were foreign-born, Ye said. People with poorer health and lower socioeconomic status were less likely to resettle in another country, she said, so Asian immigrants became a 'very positively selected' group that's 'healthier and more successful economically compared with both the source and the destination populations.'
By contrast, Ye said, U.S.-born Asians were immediately exposed to the country's cultural and political realities. Socioeconomic status has a particularly strong influence on health outcomes, as college-educated older Asian Americans saw a slight decline in disability, while those without a degree saw an increase.
While the data didn't contain mental health measures, like loneliness and anxiety, Ye said it's possible that these conditions could have also contributed to stagnating health outcomes.
'In a way,' Ye said, 'U.S.-born Asians are both less selected and more exposed throughout their lifetime.'
Mirza said a point of further study could be desegregated research on the impact of migration history on health outcomes. First-generation Vietnamese and Cambodian refugees, for example, survived war, famine and genocide. Research has shown that exposure to these adverse conditions could contribute to 'altered diets and physiological capacity' in their U.S.-born children, who are now advancing in age, Mirza said.
Mirza also emphasized a need to study the impact of social isolation on Asian seniors, which she said is gradually emerging as a social determinant of health as much as smoking and alcohol use.
'We need to see what social isolation looks like for foreign-born Asians Americans and U.S.-born Asians Americans,' she said, 'and the extent to which social ties are preserved within these groups.'
This article was originally published on NBCNews.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Exploring High Growth Tech Stocks In Asia
As global markets react to economic data and rate cut speculations, the Asian tech sector is drawing attention with its potential for high growth amidst easing U.S.-China trade tensions. In this dynamic environment, identifying stocks with strong innovation capabilities and resilience to market fluctuations can be key for investors looking to capitalize on the region's technological advancements. Top 10 High Growth Tech Companies In Asia Name Revenue Growth Earnings Growth Growth Rating Accton Technology 22.79% 22.79% ★★★★★★ Shanghai Huace Navigation Technology 25.38% 24.34% ★★★★★★ PharmaEssentia 31.53% 65.34% ★★★★★★ Fositek 31.22% 40.16% ★★★★★★ Eoptolink Technology 33.64% 33.77% ★★★★★★ Shengyi Electronics 26.23% 37.08% ★★★★★★ Zhejiang Meorient Commerce Exhibition 26.71% 35.89% ★★★★★★ Gold Circuit Electronics 26.64% 35.16% ★★★★★★ eWeLLLtd 24.93% 24.09% ★★★★★★ CARsgen Therapeutics Holdings 100.40% 118.16% ★★★★★★ Click here to see the full list of 180 stocks from our Asian High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Shanghai OPM Biosciences Simply Wall St Growth Rating: ★★★★★☆ Overview: Shanghai OPM Biosciences Co., Ltd. operates by offering cell culture media and CDMO services both in China and internationally, with a market capitalization of CN¥6.39 billion. Operations: The company generates revenue through the provision of cell culture media and CDMO services across domestic and international markets. It holds a market capitalization of approximately CN¥6.39 billion. Shanghai OPM Biosciences, amidst a challenging year with earnings contraction by 67.3%, still projects robust future growth, with anticipated revenue and earnings increases of 23.8% and 53.6% annually, outpacing the Chinese market norms of 12.9% and 23.9%, respectively. Despite a significant drop in profit margins from 19.4% to 5.4%, the firm maintains positive free cash flow and is set for a pivotal shareholders meeting that could steer its strategic direction amidst these volatile conditions. This biotech entity's commitment to innovation is evident from its R&D focus, although specific financials on this expenditure aren't disclosed here; such investment is critical in sustaining long-term competitiveness in the fast-evolving sector where technological advancements rapidly redefine market dynamics. Click to explore a detailed breakdown of our findings in Shanghai OPM Biosciences' health report. Review our historical performance report to gain insights into Shanghai OPM Biosciences''s past performance. Taiwan Union Technology Simply Wall St Growth Rating: ★★★★★☆ Overview: Taiwan Union Technology Corporation manufactures and sells copper foil substrates, adhesive sheets, and multi-layer laminated boards both in Taiwan and internationally, with a market capitalization of NT$87.56 billion. Operations: The company focuses on producing copper foil substrates, adhesive sheets, and multi-layer laminated boards for both domestic and international markets. Its revenue model is centered around these core products, contributing significantly to its financial performance. Taiwan Union Technology has demonstrated robust financial performance, with a significant 19.2% annual revenue growth and an impressive 31.8% increase in earnings per year, outstripping the Taiwanese market norms of 10.1% and 15.3%, respectively. The company's commitment to innovation is underscored by its R&D investments, crucial for maintaining competitiveness in the rapidly evolving tech landscape. Recent dividends and amendments to company bylaws reflect proactive governance, aligning with strategic goals that could shape its trajectory in Asia's high-tech sector. Take a closer look at Taiwan Union Technology's potential here in our health report. Gain insights into Taiwan Union Technology's past trends and performance with our Past report. CELSYS Simply Wall St Growth Rating: ★★★★☆☆ Overview: CELSYS, Inc. operates in the content creation solutions sector in Japan and has a market capitalization of ¥53.32 billion. Operations: The company focuses on providing content creation solutions in Japan. It operates through various revenue streams, primarily driven by software sales and related services. CELYS is actively enhancing its financial agility and market presence, as evidenced by its recent share repurchase program aimed at improving capital efficiency. The initiative to buy back 500,000 shares for ¥500 million underscores a strategic approach to capital management amidst evolving business conditions. Additionally, the establishment of CELSYS UK Ltd. marks a significant step in expanding global payment solutions, aligning with the company's growth trajectory in software offerings like CLIP STUDIO PAINT. This expansion not only diversifies their service platform but also promises to bolster corporate value over time. With an impressive forecast of 24.2% annual earnings growth and a revenue increase expectation of 10.3% per year outpacing Japan's market average, CELSYS is poised to strengthen its position in the competitive tech landscape through these calculated operational enhancements and financial strategies. Dive into the specifics of CELSYS here with our thorough health report. Understand CELSYS' track record by examining our Past report. Turning Ideas Into Actions Click this link to deep-dive into the 180 companies within our Asian High Growth Tech and AI Stocks screener. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Contemplating Other Strategies? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688293 TPEX:6274 and TSE:3663. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Los Angeles Times
2 days ago
- Los Angeles Times
Trump told polluters to email him for an exemption. In California, three places have already been approved
Three industrial facilities in California have received exemptions from the U.S. Environmental Protection Agency to emit a carcinogenic chemical after the Trump administration invited large emitters to bypass key provisions of the Clean Air Act by simply sending an email. The EPA in March announced that it would allow large stationary sources of air pollution — that is, sources that aren't vehicles — to apply for an exemption that would enable them to avoid regulations that limit hazardous emissions. The provision in question applies to the regulation of nearly 200 pollutants, including mercury, arsenic, benzene and formaldehyde. The nation's top environmental agency said the exemptions could be granted under the president's authority 'if the technology to implement the standard is not available and it is in the national security interests of the United States to do so.' Environmental groups were outraged by the announcement — dubbing the email offer as an 'inbox from hell.' As of publication, at least 340 facilities nationwide have received or applied for exemptions from the EPA, including 87 in Texas, 51 in Louisiana and 18 in Pennsylvania, according to a tracker created by the nonprofit Environmental Defense Fund. So far, three facilities in California have applied for and received approval. All three belong to Sterigenics, a company that provides industrial sterilization technology for medical devices and other commercial products at two locations in Los Angeles and one in San Bernardino County. The rule from which they are seeking relief applies to a chemical known as ethylene oxide, or EtO, which is commonly used to sterilize medical devices that can't be cleaned using steam or radiation. An estimated 50% of sterile medical devices in the U.S. are treated with EtO. The colorless gas is also used to make chemicals found in products such as antifreeze, detergents, plastics and adhesives. Yet the EPA's own website notes that short-term exposure to EtO by inhalation can cause adverse health effects including headaches, dizziness, nausea, fatigue, respiratory irritation, gastrointestinal distress and vomiting. Long-term exposure is even worse, with the EPA website noting that 'EtO is a human carcinogen. It causes cancer in humans.' Specifically, chronic exposure to ethylene oxide over many years increases the risk of cancers of the white blood cells, such as non-Hodgkin lymphoma, as well as breast cancer, according to the EPA. Children are particularly susceptible to its health risks. Granting exemptions for such emissions is 'something we should all be concerned about,' said Will Barrett, assistant vice president for nationwide clean air policy at the American Lung Assn. 'The public counts on these types of protections to ensure that their families are limiting their exposures to cancer-causing and other health risk-inducing pollutants,' Barrett said. 'And to the extent that these exemption requests are allowed to undermine that, or to delay and continue the pollution that people are being exposed to — that can have deadly consequences.' The Biden administration took steps to strengthen regulations for ethylene oxide under its amended air toxics standards in 2024, designed to reduce the amount of EtO released from commercial sterilizers by 90% and lessen the hazards for nearby communities. The Trump administration instead argued those regulations place 'severe burdens on commercial sterilization facilities,' and risk making sterile medical devices unavailable to patients who need them. 'The continued utilization of ethylene oxide by commercial sterilization facilities is essential to ensuring that our Nation provides its sick and injured with the best outcomes possible — an objective that is at the forefront of the Federal Government's responsibility to the American people,' Trump wrote in a July executive order. Trump in that same order listed nearly 40 facilities receiving exemptions from EtO compliance deadlines for two years, including the Southern California plants belonging to Sterigenics, one in Ontario, and two across the street from each other in Vernon. In a statement, a Sterigenics spokesperson said the company 'remains committed to operating safe facilities that protect patients, employees and communities.' 'The company has proactively implemented additional enhancements to further reduce already negligible levels of EtO emissions,' the statement said. 'This extension to the timeline will allow Sterigenics to continue to make thoughtful, proactive investments and focus resources on ensuring stable, reliable compliance.' According to public data, the two Sterigenics plants in Vernon released a combined 78 lbs of ethylene oxide emissions in 2024, while the one in Ontario released 612 lbs. By comparison, one of the largest ethylene oxide emitters in the country, the Union Carbide plant in Louisiana, emitted 6,894 lbs. in 2024. The federal government also granted that facility an exemption. This is not the first time Sterigenics has faced scrutiny. In 2022, the South Coast Air Quality Management District issued violation notices for improperly handling ethylene oxide to Sterigenics and another company called Parter Medical Products in Carson for improper handling of ethylene oxide. Biden's standards are set to go into effect in mid-2026. The Trump administration has said one reason it is issuing these exemptions is that the technology to implement these stricter standards 'does not exist.' But the Biden administration would not have finalized the rules if such technology were not available, according to Ellen Robo, senior manager of clean air policy and analytics at the Environmental Defense Fund, who helped create the tracker. 'The standards that are now being ignored by these exemptions were carefully considered,' Robo said. 'And with this arbitrary designation, they are being allowed to pollute in these communities with very little notice.' Robo said at least 10 more sterilization plants in California are governed by the ethylene oxide standards, and it's likely that they have also applied for an exemption. They are located in Los Angeles, Orange, San Diego, Riverside, Sacramento and Marin counties. Thinking nationally, this is just one of eight rules for which the EPA has recently offered exemptions via email. The others include rules governing mercury and air toxics; polymers and resins; rubber tires; copper smelting; and coal power, among others. 'These are things that cause cancer, cause developmental delays in children and babies,' Robo said. 'These are many of the most toxic pollutants.' The EPA's exemption template asked applicants to explain why they can't currently meet the emissions reduction goals and why an extension is in the national security interests of the country. The EPA said an email alone doesn't guarantee an exemption but that the president 'will make a decision on the merits.' The two-year exemptions can potentially be renewed, the agency said. While California so far has been granted fewer exemptions than some other states, it also has consistently ranked as one of the worst states for air quality in the nation, said Barrett of the American Lung Assn. The group's most recent annual 'State of the Air' report ranked San Bernardino as the nation's most polluted county for ozone and particle pollution, while Los Angeles has been ranked the nation's smoggiest city 25 of the last 26 years. 'For the millions and millions of people — and hundreds of thousands of children — living with asthma and other respiratory illnesses that people are dealing with on a daily basis, any erosion of the clean air protections under the Clean Air Act is a real step backward and a rejection of decades of peer-reviewed scientific literature about the harms of air pollution,' Barrett said.
Axios
2 days ago
- Axios
At-home cervical cancer test rolls out in California
The first FDA-approved at-home cervical cancer screening device launched this week in California. Why it matters: Cervical cancer is largely preventable, yet 1 in 4 U.S. women aren't up to date on screenings for the disease, per the CDC. Teal Health's goal is to make the testing experience feel less invasive than a Pap smear, which can often cause pain. Driving the news: The Teal Wand allows people to self-collect a vaginal sample to test for HPV, the virus that causes nearly all cervical cancers. The San Francisco women's health company spearheading the device says it uses the same HPV test used in clinics and merely differs in the method of collection. The big picture: California records about 7.3 cervical cancer cases per 100,000 people every year, slightly under the national rate of 7.5. The incidence rate varies among racial groups, however, with Hispanics generally seeing higher figures. Nationwide, Black and Indigenous people also experience higher rates of cervical cancer and mortality compared to white women. "Several studies have shown that the availability of self-screening can boost participation in cervical cancer screening among underscreened persons—a population most likely to benefit in terms of cancer prevention," UCSF obstetrician-gynecologist George F. Sawaya told Axios via email. In 2023, cervical cancer screenings in the U.S. remained 14% lower than pre-pandemic levels, per a March journal article. Yes, but: It's equally critical to ensure those with positive test results get reliable follow-ups and treatment, Sawaya added. How it works: To take a sample, the wand — similar to a tampon in its dimensions — is inserted into the vagina and deploys a sponge to collect cells from the cervix. Once the sponge is extracted, it's placed in a vial and mailed to the lab. Teal medical providers then review the results and follow up via telehealth. The kit, which is shipped to your door, is available for purchase online and costs $99 with in-network insurance and $249 via credit card or HSA/FSA payment. By the numbers: Self-collected samples using the wand have proven to detect cervical precancer 96% of the time, similar to clinician-collected ones, Teal Health's 16-site clinical trials found. Eighty-six percent of participants said they'd be more likely to stay up to date with screenings if they could do it at home, per the trials. What they're saying: A lot of people don't recognize the importance of getting tested regularly because it's not always clear what a Pap smear is for, Teal Health co-founder and CEO Kara Egan told Axios. Lack of appointments, time conflicts and discomfort with the exam are also top reasons for not screening, Egan added. The wand was designed to alleviate those concerns, she said, offering the "same accuracy, but just comfortably and privately from home."
